Seattle Cancer Care Alliance

Candel Therapeutics Announces Two Executive Leadership Appointments

Retrieved on: 
Wednesday, September 7, 2022
CEO, Technology, Virus, GSK, CADL, Infection, Internal medicine, LTD, Content discovery platform, Certified Public Accountant, GLOBE, Company, Smallpox, Patient, Deloitte, Cancer, University of Washington Department of Bioengineering, Seattle Cancer Care Alliance, Board, Genzyme, Duke University, SEC, CFO, GlaxoSmithKline, Nasdaq, MS, Treasurer, New England Baptist Hospital, Therapy, Immunogenic cell death, Disease, Acer, Commonwealth, HSV, Faculty, HIV, ViiV Healthcare, Fred Hutchinson Cancer Research Center, Private Securities Litigation Reform Act, CMO, University, IPO, HIV/AIDS, Epidemiology, Family, Pharmaceutical industry, Management, Vaccine, Fellow of the Academy of Medical Sciences, Akebia, Candel, MD, Doctor of Philosophy, Boston College

Mr. Amello and Dr. Nichols together bring over five decades of biopharmaceutical experience to Candel.

Key Points: 
  • Mr. Amello and Dr. Nichols together bring over five decades of biopharmaceutical experience to Candel.
  • He was instrumental in shaping the Company as we executed our IPO in 2021 and has continued to provide valuable strategic guidance to Candel.
  • On behalf of the board, the leadership team and all of the Candel employees, we wish him well.
  • Mr. Amello comes to Candel from Saniona AB, a rare disease biotech company where he served as CFO.

California Cancer Coalition Celebrates State Legislature’s Passage of Landmark Cancer Care Access Bill, Urges Governor Newsom to Sign

Retrieved on: 
Tuesday, September 6, 2022
Public Policy, Government, State, Local, Oncology, Public Policy, Health, Other Policy Issues, Healthcare Reform, Hospitals, African Americans, Breast cancer, National Cancer Institute, Research, Technology, CEO, Cancer, Survival, Legislation, National Cancer Intelligence Network, CAR, Insurance, City of Hope, YouTube, City, California State Legislature, Â, LinkedIn, Diagnosis, California Senate Bill 420, In Honor: A Compilation to Beat Cancer, Organization, State legislature, Advocacy, Assembly, CCID, Legislature, Oncology, Patient, Instagram, Cancer Treatment Centers of America, Immunotherapy, Haematopoietic system, Twitter, Public policy, Policy, Translational Genomics Research Institute, Diabetes, Helen, Woman, Medi-Cal, Seattle Cancer Care Alliance, Health insurance, Medical imaging, Pharmaceutical industry, Hospital, Hope, Facebook

The Cancer Care Is Different (CCID) Coalition applauds the California State Legislature for passing the California Cancer Care Equity Act (SB 987) , a bill that would expand access to specialized cancer care for Medi-Cal patients who receive a complex cancer diagnosis.

Key Points: 
  • The Cancer Care Is Different (CCID) Coalition applauds the California State Legislature for passing the California Cancer Care Equity Act (SB 987) , a bill that would expand access to specialized cancer care for Medi-Cal patients who receive a complex cancer diagnosis.
  • The California Cancer Care Equity Act (CCCEA) now heads to the desk of Governor Gavin Newsom for his signature, which would help the most vulnerable populations of California seek optimal cancer care services more easily, such as genomic testing, precision medicine-based care, subspecialty expertise and clinical trials.
  • We hope Governor Newsom will support this effort to connect more Californians, particularly those from historically disadvantaged communities, to the cancer care that gives them the best shot at survival.
  • The California Cancer Care Equity act is a crucial step toward addressing those inequities and we urge Gov.

SignatureCare Emergency Center Honors 1st DAISY Award Recipient for Nursing Excellence, Extraordinary Compassionate Care to Patients and their Families

Retrieved on: 
Wednesday, August 31, 2022
University, Hospital, Program, University of Washington Medical Center, Director of Operations, RN, Immune thrombocytopenic purpura, ITP, Seattle Cancer Care Alliance, Hope, Copperfield, Idiopathic disease, Nursing, Organization, DAISY, School, Immune system, Life, Family, Patient, Medicine

HOUSTON, Aug. 31, 2022 /PRNewswire-PRWeb/ -- SignatureCare Emergency Center has awarded its 1st DAISY Award For Extraordinary Nurses to Bridget Castillo, RN, a Staff Nurse at the company's Odessa facility.

Key Points: 
  • HOUSTON, Aug. 31, 2022 /PRNewswire-PRWeb/ -- SignatureCare Emergency Center has awarded its 1st DAISY Award For Extraordinary Nurses to Bridget Castillo, RN, a Staff Nurse at the company's Odessa facility.
  • The company announced this week that Castillo was chosen for the award for giving extraordinary and compassionate care to her patients and families daily.
  • According to Rhonda Abbe, SignatureCare Emergency Center's Director of Operations, SignatureCare's purpose for giving the DAISY Award For Extraordinary Nurses is to honor its emergency room nurses who go above and beyond to give extraordinary and compassionate care to patients and their families.
  • "Our nurses do a great job caring for our patients, but sometimes, we witness extraordinary and compassionate care and service.

Telix Showcasing Innovation in Theranostics at SNMMI

Retrieved on: 
Monday, June 6, 2022
Australian Securities Exchange, SNMMI, PET, Seattle Cancer Care Alliance, Company, PSMA, Research, Marketing, MTR, Food, LinkedIn, Detection, TGA, Forward-looking statement, University of Washington, PCA, Gallium, TLX, Prostate cancer, Multimedia, University, Prostate, FDA, Patient, PDT, Industry, Molecular imaging, Scottish Criminal Cases Review Commission, Nuclear medicine, Degenerative disease, ASX, Date-time group, Regulation of tobacco by the U.S. Food and Drug Administration, View, Medical imaging, Pharmaceutical industry, Animal, Telix, Radiology

SNMMI presentation details are as follows:

Key Points: 
  • SNMMI presentation details are as follows:
    Sponsored Symposium: PSMA: the next frontier in Theranostics - transforming PCa care.
  • Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR).
  • Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States.
  • Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases.

Mediaplanet and Dr. Bertalan Meskó Team Up To Spread Awareness on the Latest Innovations in Cancer Care

Retrieved on: 
Wednesday, March 30, 2022
USA TODAY, OR, College of Healthcare Information Management Executives, HIMSS, Telehealth, AMSN, NEW, SCCA, College, NLN, Caregiver, Quality, American Society of Clinical Oncology, Woman, Hospital, Cancer, Man, Society of Gynecologic Oncology, Seattle Cancer Care Alliance, CHIME, National League for Nursing, Association, Technology, International Society, Healthcare Information and Management Systems Society, ACCC, ASCO, Gynecologic Oncology (journal), Verizon Communications, SGO, Awareness, National League, Academy of Medical-Surgical Nurses, Patient, Medicine

NEW YORK, March 30, 2022 /PRNewswire-PRWeb/ -- Approximately 39.5 percent of men and women will be diagnosed with cancer at some point of their lifetime. These past two years have presented dramatic challenges for cancer patients receiving the proper treatment and screenings they need. Technology has paved the way to a new future of care that will have a long-lasting impact within the field.

Key Points: 
  • Mediaplanet's "Innovations in Cancer Care" campaign, found within USA TODAY, OR Today, and online, spreads awareness on the important advancements paving the way to a new future of cancer care.
  • These past two years have presented dramatic challenges for cancer patients receiving the proper treatment and screenings they need.
  • Technology has paved the way to a new future of care that will have a long-lasting impact within the field.
  • In Mediaplanet's new "Innovations in Cancer Care" campaign, Dr. Bertalan Mesk, director of The Medical Futurist, discusses just how technological advancements are supporting our hospitals, caregivers, and patients at such a crucial time.

Children's Hospital of Philadelphia Establishes the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy

Retrieved on: 
Monday, March 28, 2022
Dream, Therapy, Seattle Cancer Care Alliance, Partnership, Degenerative disease, Roswell Park Comprehensive Cancer Center, CAR, Research, Hospital, Prussia, CHOP, Cancer, Food, Kellys, University, ALL, Immune system, Health, Transplant, Cell, Acute lymphoblastic leukemia, Regulation of tobacco by the U.S. Food and Drug Administration, Child, Inherited disorders of trafficking, Inauguration, FDA, Novartis, Division, Patient, Children's Hospital of Philadelphia, Pharmaceutical industry

PHILADELPHIA, March 28, 2022 /PRNewswire/ -- Today Children's Hospital of Philadelphia (CHOP) announced that it has received a significant gift from Susan and Steve Kelly, local philanthropists and long-time supporters of CHOP, to establish the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy. The new Center, led by Dr. Stephan Grupp, will allow CHOP to create a more robust infrastructure to expand pediatric clinical trials and accelerate the U.S. Food and Drug Administration (FDA) approval of novel treatments; increase the pipeline of innovative therapeutics and diagnostics; recruit and train top investigators and postdoctoral researchers to become the next generation of cancer immunotherapy experts; and increase equity and access to cell therapy clinical trials for socioeconomically disadvantaged patients.

Key Points: 
  • PHILADELPHIA, March 28, 2022 /PRNewswire/ --Today Children's Hospital of Philadelphia (CHOP) announced that it has received a significant gift from Susan and Steve Kelly, local philanthropists and long-time supporters of CHOP, to establish the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy.
  • Emily Whitehead, the first child to undergo experimental CAR T-cell therapy treatment, remains cancer free nearly 10 years later.
  • "We are honored our gift will help CHOP and Dr. Grupp to unlock the tremendous potential of cancer immunotherapies," said Steve and Susan Kelly.
  • About Children's Hospital of Philadelphia:A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital.

TriSalus Life Sciences Expands Clinical Executive Team and Scientific Advisors in Support of Company’s Focus to Overcome Liver and Pancreatic Cancer Treatment Barriers and Enable More Patients to Benefit From Immunotherapy

Retrieved on: 
Thursday, February 10, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Clinical Trials, Fellowship of the Royal Colleges of Surgeons, Society of Interventional Radiology, American Board of Radiology, MedStar Georgetown University Hospital, Harlem Hospital Center, Growth, Radiology, Oncology, Surgical oncology, United States Air Force Scientific Advisory Board, Memorial Sloan Kettering Cancer Center, Rush University Medical Center, Doctor of Philosophy, Research, Chicago Medical School, Uterine fibroid, Trauma Center, Jordan, DRS, Trauma center, American College, Rosalind Franklin University of Medicine and Science, Patient, Trauma, Pancreatic cancer, University, Liver, Columbia University Irving Medical Center, Pancreas, American Board of Commissioners for Foreign Missions, Immunotherapy, Memorial, Radiation, Therapy, Liver cancer in cats and dogs, Columbia University, Seattle Cancer Care Alliance, FACS, Medical imaging, Dentistry, Science, Cancer, MD

Alexander Kim and John Hardaway, as director of interventional oncology clinical strategies and strategic immunotherapy advisor, respectively.

Key Points: 
  • Alexander Kim and John Hardaway, as director of interventional oncology clinical strategies and strategic immunotherapy advisor, respectively.
  • Throughout his career, Dr. Kim has led or participated in clinical trials related to the study of liver cancers, uterine fibroids and symptoms of benign prostate hypertrophy.
  • Following his clinical training, which included a research fellowship at Memorial Sloan-Kettering Cancer Center, he served as Chief of the vascular and interventional radiology division at Georgetown University Hospital.
  • He currently serves as a cancer liaison physician on the American College of Surgeons Commission on Cancer.

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Retrieved on: 
Friday, January 7, 2022
Clinical trial, B cell, University, Drug Quality and Security Act, Translation, Research, Associate professor, Ownership, Patient, Chronic lymphocytic leukemia, Forward-looking statement, Hematological Cancer Research Investment and Education Act, Fortress Biotech, Securities Exchange Act of 1934, University of Washington School of Medicine, U.S. Securities and Exchange Commission, CD20, CLL, Oncology, Laboratory, Regulation, Transplant, Society, Treatment, Fred Hutchinson Cancer Research Center, Private Securities Litigation Reform Act, Division, Tandem, NASDAQ, SEC, Generation, Medicine, Seattle Cancer Care Alliance, Patent, Mustang, GLOBE, Center for International Blood and Marrow Transplant Research, Associate, CAR, Securities Act of 1933, Lists of diseases, Macroglobulinemia, Center, Toxicity, Pharmaceutical industry

MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Research Center (Fred Hutch).

Key Points: 
  • MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Research Center (Fred Hutch).
  • We look forward to the updated data that will be presented by Fred Hutch at the 2022 Tandem Meetings, in particular for patients with diffuse large B cell lymphoma and Waldenstroms macroglobulinemia.
  • We also look forward to advancing our MB-106 CD20-targeted CAR T cell therapy program towards a multicenter trial under Mustangs IND in the current quarter.
  • It should be noted that Mustang Bio has introduced minor improvements to its cell processing to facilitate eventual commercial launch of the product.

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Retrieved on: 
Monday, December 13, 2021
Fred Hutchinson Cancer Research Center, Forward-looking statement, Mustang, U.S. Securities and Exchange Commission, Fortress Biotech, Food, Seattle Cancer Care Alliance, Clinical trial, Physician, Drug Quality and Security Act, Securities Exchange Act of 1934, Hematological Cancer Research Investment and Education Act, Follicular lymphoma, CR, Regulation, Ownership, Private Securities Litigation Reform Act, ORR, Lists of diseases, CD20, B cell, Securities Act of 1933, NASDAQ, B-cell lymphoma, SEC, Associate professor, CD19, Research, Safety, Patient, Patent, Associate, Laboratory, Investor relations, GLOBE, DRS, Shadman, Chronic lymphocytic leukemia, Cytokine release syndrome, EST, CAR, CLL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Translation, Pharmaceutical industry

WORCESTER, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”). MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Research Center (“Fred Hutch”).

Key Points: 
  • Durable responses were observed in a wide range of hematologic malignancies including follicular lymphoma, diffuse large B-cell lymphoma, CLL, and Waldenstroms macroglobulinemia.
  • An overall response rate (ORR) of 95% and complete response (CR) rate of 65% was observed in all patients across all dose levels.
  • In patients with follicular lymphoma (n=15), the ORR was 93% and the CR rate was 73%.
  • Enrollment for this study remains robust for patients with CD20+ B-NHLs and CLL, including patients with prior CAR T treatment.

Seattle Cancer Care Alliance Clinicians Present New Research at 63rd Annual Meeting of the American Society of Hematology

Retrieved on: 
Thursday, December 9, 2021
Health, Science, Stem Cells, Research, Oncology, Leukemia, Research, National Comprehensive Cancer Network, Lymphoma, Patient, Multiple myeloma, Lymphatic system, Seattle Cancer Care Alliance, NCCN, MD, Chronic lymphocytic leukemia, SCCA, HCT, Society, CD20, ASH, Pharmaceutical industry

Seattle Cancer Care Alliance (SCCA), the only National Comprehensive Cancer Network (NCCN)-designated cancer center in Washington state, today announced that more than 20 of the organizations clinicians will showcase new research at the 63rd Annual Meeting of the American Society of Hematology (ASH), taking place December 11-14, 2021, in Atlanta.

Key Points: 
  • Seattle Cancer Care Alliance (SCCA), the only National Comprehensive Cancer Network (NCCN)-designated cancer center in Washington state, today announced that more than 20 of the organizations clinicians will showcase new research at the 63rd Annual Meeting of the American Society of Hematology (ASH), taking place December 11-14, 2021, in Atlanta.
  • SCCA clinicians and researchers will unveil findings on areas of investigation into treatments for patients with various hematological malignancies, including lymphoma, leukemia and myeloma.
  • Our team at Seattle Cancer Care Alliance is committed to understanding, developing and advancing cutting-edge cancer treatments, said Nancy Davidson, MD , president and executive director of SCCA.
  • For more information about SCCA physician-researchers presenting their pioneering research at the 63rd ASH annual meeting, visit https://www.seattlecca.org/conference/ash-2021 .